These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25384899)

  • 1. Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
    Sharma R; Litchfield J; Bergman A; Atkinson K; Kazierad D; Gustavson SM; Di L; Pfefferkorn JA; Kalgutkar AS
    Drug Metab Dispos; 2015 Feb; 43(2):190-8. PubMed ID: 25384899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and excretion of (
    Sharma R; Bergman A; Litchfield J; Atkinson K; Kazierad DJ; Kalgutkar AS
    Xenobiotica; 2019 Dec; 49(12):1447-1457. PubMed ID: 30747552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA; Guzman-Perez A; Litchfield J; Aiello R; Treadway JL; Pettersen J; Minich ML; Filipski KJ; Jones CS; Tu M; Aspnes G; Risley H; Bian J; Stevens BD; Bourassa P; D'Aquila T; Baker L; Barucci N; Robertson AS; Bourbonais F; Derksen DR; Macdougall M; Cabrera O; Chen J; Lapworth AL; Landro JA; Zavadoski WJ; Atkinson K; Haddish-Berhane N; Tan B; Yao L; Kosa RE; Varma MV; Feng B; Duignan DB; El-Kattan A; Murdande S; Liu S; Ammirati M; Knafels J; Dasilva-Jardine P; Sweet L; Liras S; Rolph TP
    J Med Chem; 2012 Feb; 55(3):1318-33. PubMed ID: 22196621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.
    Sharma R; Litchfield J; Atkinson K; Eng H; Amin NB; Denney WS; Pettersen JC; Goosen TC; Di L; Lee E; Pfefferkorn JA; Dalvie DK; Kalgutkar AS
    Drug Metab Dispos; 2014 Nov; 42(11):1926-39. PubMed ID: 25142735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
    Erion DM; Lapworth A; Amor PA; Bai G; Vera NB; Clark RW; Yan Q; Zhu Y; Ross TT; Purkal J; Gorgoglione M; Zhang G; Bonato V; Baker L; Barucci N; D'Aquila T; Robertson A; Aiello RJ; Yan J; Trimmer J; Rolph TP; Pfefferkorn JA
    PLoS One; 2014; 9(5):e97139. PubMed ID: 24858947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators.
    Ghosh A; Maurer TS; Litchfield J; Varma MV; Rotter C; Scialis R; Feng B; Tu M; Guimaraes CR; Scott DO
    Drug Metab Dispos; 2014 Oct; 42(10):1599-610. PubMed ID: 25024402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.
    Bergman A; Bi YA; Mathialagan S; Litchfield J; Kazierad DJ; Pfefferkorn JA; Varma MVS
    Clin Pharmacol Ther; 2019 Oct; 106(4):792-802. PubMed ID: 30919935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.
    Ryder TF; Bergman A; King-Ahmad A; Amin NB; Lall MS; Ballard TE; Kalgutkar AS
    Xenobiotica; 2022 Mar; 52(3):240-253. PubMed ID: 35382680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
    Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
    Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
    Stevens BD; Litchfield J; Pfefferkorn JA; Atkinson K; Perreault C; Amor P; Bahnck K; Berliner MA; Calloway J; Carlo A; Derksen DR; Filipski KJ; Gumkowski M; Jassal C; MacDougall M; Murphy B; Nkansah P; Pettersen J; Rotter C; Zhang Y
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6588-92. PubMed ID: 24239482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
    Mamidi RN; Cuyckens F; Chen J; Scheers E; Kalamaridis D; Lin R; Silva J; Sha S; Evans DC; Kelley MF; Devineni D; Johnson MD; Lim HK
    Drug Metab Dispos; 2014 May; 42(5):903-16. PubMed ID: 24568888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
    Sarabu R; Bizzarro FT; Corbett WL; Dvorozniak MT; Geng W; Grippo JF; Haynes NE; Hutchings S; Garofalo L; Guertin KR; Hilliard DW; Kabat M; Kester RF; Ka W; Liang Z; Mahaney PE; Marcus L; Matschinsky FM; Moore D; Racha J; Radinov R; Ren Y; Qi L; Pignatello M; Spence CL; Steele T; Tengi J; Grimsby J
    J Med Chem; 2012 Aug; 55(16):7021-36. PubMed ID: 22809456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers.
    Greene RJ; Davis JA; Subramanian R; Deane MR; Emery MG; Slatter JG
    Drug Metab Dispos; 2012 May; 40(5):928-42. PubMed ID: 22328582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
    Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
    Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.